Strong approval of HBC products from health authorities

Health Canada confirms health benefits of two products after thorough scientific assessment.
Colla Go 1200x490

Following an extensive scientific assessment process, the Canadian health authorities today confirms that Hofseth BioCare's products have an effect in the treatment of iron deficiency anemia, and that the products provide an increased level of antioxidants.

HBC has now received approval for the use of claims focused on maintaining healthy levels of iron and white blood cells, as well as blood components required for oxygen transport. This is the first non-iron based product to receive regulatory approval on such claims.

As the bioactive peptides in ProGo® and CollaGo® do not contain iron, they are free from the well-known gastrointestinal (GI) side effects seen with iron tablets such as nausea, constipation, and a metallic taste.

Approved Recommended Use and Purpose are:

  • “helps maintain healthy levels of ferritin and hemoglobin
  • helps maintain healthy levels of blood components required for oxygen transport
  • provides antioxidants for the maintenance of good health
  • helps promote healthy skin”.

Internationally recognized claims
HBC’s bioactive peptides can now offer an alternative solution to this common problem without the need for iron which frequently results in GI irritation. Furthermore, Health Canada’s “qualified health claims” are internationally recognized by most Asian countries and therefore will be passported for their use in those countries too.

Of note, the bioactive peptides do not contain any actual antioxidant compounds (natural or added), rather the bioactive peptides contained in ProGo ® and CollaGo ® upregulate the body’s natural antioxidant genes to deliver this vital health benefit.

Prescription drug claim for the treatment of iron deficiency anemia

HBC has identified the active peptide fraction leading to the increase in ferritin and hemoglobin. This fraction consists of a limited number of structurally related peptides. During H1 2021, having already identified one or more of these peptides that are responsible for the increase in ferritin, HBC plans to produce a new composition of matter claim and commence clinical trial work for the prescription drug claim for the treatment of iron deficiency anemia.

Big market in North America

HBC can now sell ProGo® and CollaGo® across the whole of North America following the unique set of Structure-Function Claims in the US.

Iron supplementation is a significant market in the US alone with approximately 20% of women, 50% of pregnant women, and 3% of men lacking sufficient iron stores in their bodies.

Read more about ProGo®
Read more about CollaGo®